As filed with the
Securities and Exchange Commission on April 20, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
Protalix BioTherapeutics, Inc.
(Exact name of Registrant as specified in its charter)
Delaware |
|
65-0643773 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
incorporation or organization) |
|
Identification No.) |
2 University Plaza, Suite 100
Hackensack, NJ 07601
(201) 696-9345
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Dror Bashan, President and Chief Executive Officer
Protalix BioTherapeutics, Inc.
2 University Plaza, Suite 100
Hackensack, NJ 07601
(201) 696-9345
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Anna T. Pinedo
Brian D. Hirshberg
Mayer Brown LLP
1221 Avenue of the Americas
New York, New York 10020-1001
(212) 506-2500
Approximate date of commencement of proposed sale to the public:
From time to time on or after the effective date of this registration statement.
If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, check the following box.
If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following box. ¨
If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement pursuant
to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. ¨
If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of
securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ |
Accelerated filer ¨ |
Non-accelerated filer x |
Smaller reporting company x |
|
Emerging growth company ¨ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standard provided pursuant to Section 7(a)(2)(B) of the Securities Act ¨
The Registrant hereby amends this Registration Statement on such
date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states
that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of
1933 or until the Registration Statement shall become effective on such date as the Commission acting pursuant to said Section 8(a),
may determine.
The information in this prospectus is not complete
and may be changed. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration
statement filed with the Securities and Exchange Commission becomes effective. This prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED APRIL
20, 2022
PROSPECTUS
$100,000,000 |
|
Common Stock
Preferred Stock
Debt Securities
Warrants |
We may from time to time offer, in one or more
series, separately or together, the following:
● our
common stock;
● our
preferred stock in one or more series;
● debt
securities in one or more series; and
● warrants to purchase our common
stock.
The aggregate public offering price of the securities
that we may offer through this prospectus will be up to $100,000,000.
We will provide the specific terms of the securities
offered by us in supplements to this prospectus, which we will deliver together with the prospectus at the time of sale. This prospectus
may not be used to sell securities unless accompanied by a prospectus supplement. Please read this prospectus and the applicable prospectus
supplement carefully before you invest in any of our securities.
We may, from time to time, offer and sell these
securities directly or through one or more underwriters, agents or dealers, through underwriting syndicates managed or co-managed by one
or more underwriters, or directly to purchasers, on or off the NYSE American at prevailing market prices or at privately negotiated prices,
on a continuous or delayed basis.
Our common stock is listed on the NYSE American under the symbol “PLX”
and on the Tel Aviv Stock Exchange under the symbol “PLX.” On April 19, 2022, the last reported sale price of our common
stock was $1.33 per share on the NYSE American and NIS 4.27 per share on the Tel Aviv Stock Exchange.
Investing in our securities involves risks.
Risks associated with an investment in our securities will be described in the applicable prospectus supplement and certain of our filings
with the Securities and Exchange Commission, as described under the caption “Risk Factors” on page 4.
None of the Securities and Exchange Commission,
the Israeli Securities Authority or any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2022
Table
of Contents
No dealer, salesman or other person has been authorized to give
any information or to make any representations in connection with the offer made by this prospectus or any prospectus supplement other
than those contained in, or incorporated by reference in, this prospectus or any prospectus supplement, and if given or made, such information
or representations must not be relied upon as having been authorized by us or any underwriter, agent or dealer. We or an authorized underwriter,
agent or dealer may also furnish you with a free writing prospectus relating to the applicable securities. This prospectus, any prospectus
supplement or any free writing prospectus does not constitute an offer to sell or a solicitation of any offer to buy any securities in
any jurisdiction to any person to whom it is unlawful to make an offer or solicitation in such jurisdiction. The delivery of this
prospectus, any prospectus supplement or any free writing prospectus at any time does not imply that the information contained herein
or therein is correct as of any time subsequent to their respective dates.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
The statements set forth and incorporated by reference
in this prospectus, which are not historical, constitute “forward- looking statements” within the meaning of Section 27A
of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended,
or the Exchange Act, including statements regarding the expectations, beliefs, intentions or strategies for the future. When used in this
prospectus, or in any document incorporated by reference in this prospectus, the terms “anticipate,” “believe,”
“estimate,” “expect,” “can,” “continue,” “could,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “will,” “would”
and words or phrases of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify
forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with
respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating
or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect
the occurrence of unanticipated events, except as may be required under applicable law. We intend that all forward-looking statements
be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject
to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied
by the forward-looking statements.
Examples of the risks and uncertainties include,
but are not limited to, the following:
| ● | risks related to the timing and progress of the preparation of an updated Biologics License Application, or BLA, for PRX-102 addressing
the Complete Response Letter, or CRL; |
| ● | risks related to the timing, progress and likelihood of final approval by the U.S. Food and Drug Administration, or the FDA, and the
European Medicines Agency, or the EMA, of a resubmitted Biologics License Application, or BLA, and of a Marketing Authorization Application,
or an MAA, respectively, for PRX-102, and, if approved, whether the use of PRX-102 will be commercially successful; |
| ● | failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several
factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack
of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow
our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance
our clinical trials; |
| ● | the risk that the FDA, the EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file
for any of our product candidates, and other risks relating to the review process; |
| ● | risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business; |
| ● | risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research
and development activities, general and administrative expenses and working capital; |
| ● | risks relating to our evaluation and pursuit of strategic alternatives; |
| ● | the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product
candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; |
| ● | risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited
to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi; |
| ● | risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish; |
| ● | risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; |
| ● | our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services; |
| ● | the impact of development of competing therapies and/or technologies by other companies; |
| ● | risks related to our supply of drug product to Pfizer; |
| ● | risks related to our expectations with respect to the potential commercial value of our product and product candidates; |
| ● | risks relating to the compliance by Fundação Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or
the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse
effect on us and may also result in the termination of such agreement; |
| ● | potential product liability risks, and risks of securing adequate levels of related insurance coverage; |
| ● | the possibility of infringing a third-party’s patents or other intellectual property rights and the uncertainty of obtaining
patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; |
● |
risks relating to changes in healthcare laws, rules and regulations in the United States, the European Union or elsewhere; and |
| ● | the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial
sites, distributors and customers. |
Given these uncertainties, you should not place
undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such
clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities
may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.
These and other risks and uncertainties are detailed
under the heading “Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2021, and are described from time to time in the reports we file with the U.S. Securities and Exchange
Commission, or the Commission.
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement
that we filed with the Commission using a “shelf” registration process. Under this shelf registration process, we may sell
shares of common stock and preferred stock, debt securities and/or warrants in one or more offerings, up to a total dollar amount of $100,000,000.
This prospectus provides you with a general description
of the securities we may offer under this prospectus. Each time we sell securities, we will provide a prospectus supplement that will
contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained
in this prospectus.
The Commission allows us to “incorporate
by reference” certain information that we file with it, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we
file later with the Commission will update automatically, supplement and/or supersede this information. Any statement contained in a document
incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of
this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is deemed to be incorporated
by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this prospectus. You should read the detailed information regarding our company,
our securities and our financial statements and the notes to those statements appearing elsewhere in this prospectus or incorporated herein
by reference.
You should read both this prospectus and the applicable
prospectus supplement together with additional information from the sources described under the caption “Where You Can Find More
Information” in this prospectus. You should not assume that the information in this prospectus, the prospectus supplements, any
free writing prospectus or any document incorporated by reference is accurate as of any date subsequent to their respective dates.
You should rely only on the information provided
or incorporated by reference in this prospectus, any free writing prospectus and any prospectus supplement, if applicable. We have not
authorized anyone to provide you with different information.
References in this prospectus to “our company,”
“we,” “our,” and “us” refer to Protalix BioTherapeutics, Inc.
OUR BUSINESS
We are a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic proteins primarily based on our proprietary ProCellEx® protein
expression system. We developed our first commercial drug product, Elelyso®, using our ProCellEx system and we are now
focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of complex recombinant therapeutic
proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms
of action. With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins that
are therapeutically superior to existing recombinant proteins currently marketed for the same indications, including applying the unique
properties of our ProCellEx system for the oral delivery of therapeutic proteins.
Pegunigalsidase alfa (PRX-102), our proprietary
plant cell culture expressed enzyme in development for the treatment of Fabry disease, is our most advanced product candidate. Our PRX-102
phase III clinical program of PRX-102 for the treatment of Fabry disease includes three separate studies: the BALANCE, BRIDGE
and BRIGHT studies. The BRIDGE and BRIGHT studies have been completed, and the last patient in the BALANCE
study received the final dose in the study in October 2021. The studies were designed to evaluate the potential superiority of PRX-102
over current therapies, demonstrate the potential for improved efficacy and better quality of life for patients with Fabry disease and
demonstrate the safety of our drug/therapy. We are also evaluating the potential of a once-monthly treatment regimen with a higher dose
of PRX-102. In addition, the phase III clinical program includes two extension studies in which subjects that participated in our
phase I/II clinical trials and our phase III clinical trials may enroll and continue to be treated with PRX-102.
On April 4, 2022, we, together with our development
and commercialization partner for PRX-102, Chiesi, announced positive topline results from our BALANCE study, a pivotal phase III
clinical trial evaluating PRX-102, 1 mg/kg, administered every two weeks, compared to agalsidase beta (Fabrazyme®) for the treatment
of Fabry disease.
On February 7, 2022, an MAA for PRX-102 was
submitted to, and subsequently validated by, the EMA. The submission was made after the October 8, 2021 meeting we held, together
with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the
scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of
the planned MAA submission for PRX-102.
On April 28, 2021, we, together with Chiesi,
announced the receipt of a CRL from the FDA regarding the PRX-102 BLA. The CRL did not report any concerns relating to the potential safety
or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of our manufacturing facility in Carmiel,
Israel, including the FDA’s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted
BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the
letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define
an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes
are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection.
In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending
items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta, a therapy used to treat Fabry patients, was recently
converted to full approval and is now an “available therapy,” which must be addressed in the context of any potential resubmission
of a BLA for PRX-102.
We and Chiesi participated in a Type A (End of
Review) meeting with the FDA on September 9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary
comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the
potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission,
given the changed regulatory landscape in the United States, will include the final two-year analyses of the BALANCE study. We
intend to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to
Fabry patients.
We have entered into two exclusive global licensing
and supply agreements (ex-U.S. and U.S.) with Chiesi for PRX-102; on October 19, 2017, Protalix Ltd., our wholly-owned subsidiary,
entered into an Exclusive License and Supply Agreement with Chiesi, or the Chiesi Ex-US Agreement, pursuant to which Chiesi was granted
an exclusive license for all markets outside of the United States to commercialize PRX-102 and on July 23, 2018, Protalix Ltd. entered
into an Exclusive License and Supply Agreement with Chiesi, or the Chiesi US Agreement, with respect to the commercialization of PRX-102
in the United States.
In addition to PRX-102, our product pipeline currently
includes, among other candidates:
1) alidornase
alfa, or PRX-110, a proprietary plant cell recombinant human DNase, which has successfully completed a phase II efficacy and safety
study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical
companies for this product candidate for various respiratory indications;
2) PRX-115,
our plant cell-expressed recombinant PEGylated uricase (urate oxidase) – a chemically modified enzyme to treat refractory gout;
and
3) PRX-119,
our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation
for NETs-related diseases.
We have licensed the rights to commercialize taliglucerase
alfa worldwide (other than Brazil) to Pfizer, and the rights to commercialize pegunigalsidase alfa worldwide to Chiesi. Otherwise, we
hold the worldwide commercialization rights to our other proprietary development candidates. In addition, we continuously evaluate potential
strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research
institutes.
RISK FACTORS
Investing in our securities involves a high degree
of risk. You should carefully consider the specific risks sets forth under the caption “Risk Factors” in the applicable prospectus
supplement and under the captions “Risk Factors” in any of our filings with the Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2021 before making an investment decision. For additional information, please see
the sources described under the caption “Where You Can Find More Information.”
USE OF PROCEEDS
We will retain broad discretion over the use of
the net proceeds of the securities we offer hereby. Unless the applicable prospectus supplement states otherwise, the net proceeds from
the securities we sell will be added to our general corporate funds and may be used for research and development expenses, clinical trials,
establishing an internal sales force for selected territories, acquisitions of new technologies or businesses, and general corporate and
administrative purposes. Until the net proceeds have been used, they will be invested primarily in short-term bank deposits or marketable
securities. If we elect at the time of the issuance of the securities to make different or more specific uses of proceeds other than as
described in this prospectus, the change in use of proceeds will be described in the applicable prospectus supplement.
DILUTION
We will set forth in a prospectus supplement the
following information regarding any material dilution of the equity interests of investors purchasing securities in an offering under
this prospectus:
| ● | the net tangible book value per share of our equity securities before and after the offering; |
| ● | the amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers in the offering;
and |
| ● | the amount of the immediate dilution from the public offering price that will be absorbed by such purchasers. |
SECURITIES WE MAY OFFER
Types of Securities
The securities we may offer from time to time by
this prospectus are:
| ● | preferred stock, which we may issue in one or more series; |
| ● | debt securities, which we may issue in one or more series; and |
| ● | warrants entitling the holders to purchase common stock. |
We will describe in a prospectus supplement, which
we will deliver with this prospectus at the time of sale, the terms of the particular securities that we may offer in the future.
The aggregate initial offering price of all securities
sold will not exceed $100,000,000. When we sell securities, we will determine the amounts of securities we will sell and the prices and
other terms on which we will sell them. We may sell securities to or through underwriters, through agents or dealers or directly to purchasers.
Additional Information
We will describe in a prospectus supplement, which
we will deliver with this prospectus, the terms of particular securities that we may offer in the future. In each prospectus supplement
we will include the following information:
|
● |
the type and amount of securities that we propose to sell; |
| ● | the initial public offering price of the securities; |
| ● | the names of the underwriters, agents or dealers, if any, through or to which we will sell the securities; |
| ● | the compensation, if any, of those underwriters, agents or dealers; |
| ● | if applicable, information about any securities exchange or automated quotation system on which the securities will be listed or traded; |
| ● | material U.S. federal income tax considerations applicable to the securities; |
| ● | any material risk factors associated with the securities; |
| ● | original issue discount, if any; |
| ● | rates and times of payment of interest, dividends or other payments, if any; |
| ● | redemption, conversion, exercise, exchange, settlement or sinking fund terms, if any; |
| ● | voting or other rights, if any; |
| ● | conversion, exchange or settlement prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the
conversion, exchange or settlement prices or rates and in the securities or other property receivable upon conversion, exchange or settlement;
and |
| ● | any other material information about the offer and sale of the securities. |
In addition, the prospectus supplement may add,
update or change the information contained in this prospectus.
DESCRIPTION OF EQUITY SECURITIES
We are a Delaware corporation. The rights of our
stockholders are governed by the Delaware General Corporation Law, our Certificate of Incorporation, as amended, and our bylaws. The following
summary of the material terms, rights and preferences of our capital stock is not complete. You should read our Certificate of Incorporation,
as amended, and our bylaws, which we refer to as our charter, for more complete information before you purchase any of our securities.
You should read these documents, copies of which are available from us upon request at the address set forth under the caption “Where
You Can Find More Information,” in order to more fully understand the terms of our common stock.
Common Stock
General. Our charter provides that
we may issue up to 120,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of preferred stock, par value
$0.0001 per share, all of which preferred stock are undesignated. As of April 15, 2022, 46,365,832 shares of our common stock were
issued and outstanding and no shares of preferred stock were issued and outstanding.
Holders of common stock are entitled to one vote
for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Accordingly, holders
of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for
election. Holders of common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally
available therefor.
In the event of our liquidation, dissolution or
winding-up, after payment of all of our debts and liabilities, the holders of our common stock are entitled to share ratably in all remaining
assets available for distribution after the payment of debts and liabilities and after provision has been made for each class of stock,
if any, having preferences over our common stock. Holders of our common stock, as such, have no preemptive or other rights and there are
no redemption provisions applicable to our common stock. All of our outstanding shares of common stock are fully paid and nonassessable.
The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the
holders of shares of any series of preferred stock that we may designate and issue in the future. In accordance with the rules of the
Tel Aviv Stock Exchange Ltd., or the TASE, and as long as our securities are listed for trading on the TASE, we are allowed to issue securities
with preferential rights relating to dividends, but such securities may not have voting rights.
Dividend Policy. We have never declared
or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to finance the growth and development
of our business and therefore do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash
dividends will be at the discretion of our board of directors and will depend upon our financial condition, operating results, capital
requirements, covenants in our debt instruments (if any), and such other factors as our board of directors deems relevant.
Transfer Agent and Registrar. The
transfer agent and registrar of our common stock is American Stock Transfer & Trust Company.
Preferred Stock
Our restated articles of incorporation, as amended,
authorizes the issuance of up to 100,000,000 shares of preferred stock with such voting rights, rights of redemption and other relative
rights and preferences as may be determined from time to time by our board of directors. Accordingly, our board of directors is empowered,
without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely
affect the voting power or other rights of the holders of our common stock. The preferred stock could be utilized, under certain circumstances,
as a method of discouraging, delaying or preventing a change in control of our company. We currently have no plan to issue any shares
of preferred stock.
Terms. You should refer to the prospectus
supplement relating to the offering of any preferred stock for specific terms of the shares, including the following terms:
| ● | title and stated or liquidation value; |
| ● | number of shares offered and initial offering price; |
| ● | voting rights and other protective provisions; |
| ● | any dividend rate(s), payment period(s) and/or payment date(s) or method(s) of calculation of any of those terms that
apply to those shares; |
| ● | date from which dividends will accumulate, if applicable; |
| ● | terms and amount of a sinking fund, if any, for purchase or redemption; |
| ● | redemption rights, including conditions and the redemption price(s), if applicable; |
| ● | listing on any national securities exchange; |
| ● | terms and conditions upon which shares will be convertible into common stock or any other securities, including the conversion price,
rate or other manner of calculation and anti-dilution provisions, if applicable; |
| ● | the relative ranking and preference as to dividend rights and rights upon liquidation, dissolution or the winding-up of our affairs,
including liquidation preference amount; |
| ● | any limitation on issuance of any series of preferred stock ranking senior to or on a parity with that series of preferred stock as
to dividend rights and rights upon liquidation, dissolution or the winding-up of our affairs; |
| ● | any other specific terms, preferences, rights, limitations or restrictions; and |
| ● | a discussion of applicable material U.S. federal income tax consequences. |
The terms of any preferred stock we issue under
this prospectus will be set forth in a certificate of designation. We will file a form of the certificate of designation as an exhibit
to the registration statement that includes this prospectus, or as an exhibit to a filing with the Commission that is incorporated by
reference into this prospectus. The description of preferred stock in any prospectus supplement will not necessarily describe all of the
terms of the preferred stock in detail. You should read the applicable certificate of designation for a complete description of all of
the terms.
Ranking. Unless we provide otherwise
in a prospectus supplement, the preferred stock offered through that supplement will, with respect to dividend rights and rights upon
our liquidation, dissolution or winding-up, rank:
| ● | senior to all classes or series of our common stock, and to all other equity securities ranking junior to the offered shares of preferred
stock; |
| ● | on a parity with all of our equity securities ranking on a parity with the offered shares of preferred stock; and |
| ● | junior to all of our equity securities ranking senior to the offered shares of preferred stock. |
The term “equity securities” does not
include convertible debt securities.
Dividends. Subject to any preferential
rights of any outstanding stock or series of stock, our preferred stockholders may be entitled to receive dividends, when and as authorized
by our board of directors, out of legally available funds, as specified in the applicable prospectus supplement.
Redemption. If we provide for a redemption
right in a prospectus supplement, the preferred stock offered through that prospectus supplement may be subject to mandatory redemption
or redemption at our option, in whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in
that prospectus supplement.
Liquidation Preference. In the event
of our voluntary or involuntary dissolution, liquidation or winding-up, the holders of any series of our preferred stock may be entitled
to receive, after distributions to holders of any series or class of our capital stock ranking senior, an amount equal to the stated or
liquidation value of the shares of the series plus, if applicable, an amount equal to accrued and unpaid dividends. If the assets and
funds to be distributed among the holders of our preferred stock will be insufficient to permit full payment to the holders, then the
holders of our preferred stock may share ratably in any distribution of our assets in proportion to the amounts that they otherwise would
receive on their shares of our preferred stock if the shares were paid in full.
Voting Rights. Unless otherwise indicated
in the applicable prospectus supplement, holders of our preferred stock will not have any voting rights, except as may be required by
applicable law.
Conversion Rights. The terms and
conditions, if any, upon which any series of preferred stock is convertible into common stock or other securities will be set forth in
the prospectus supplement relating to the offering of those shares of preferred stock. These terms typically will include:
| ● | the number of shares of common stock or other securities into which the preferred stock is convertible; |
| ● | the conversion price (or manner of calculation); |
| ● | provisions as to whether conversion will be at the option of the holders of the preferred stock or at our option; |
| ● | the events, if any, requiring an adjustment of the conversion price; and |
| ● | provisions affecting conversion in the event of the redemption of that series of preferred stock. |
Transfer Agent and Registrar. We
will identify the transfer agent and registrar for any series of preferred stock offered by this prospectus in a prospectus supplement.
Warrants
We may issue warrants for the purchase of common
stock. If we offer warrants, we will describe the terms of the warrants in a prospectus supplement. Warrants may be offered independently,
together with other securities offered by any prospectus supplement, or through a dividend or other distribution to stockholders and may
be attached to or separate from other securities. Warrants may be issued under a written warrant agreement to be entered into between
us or the holder or beneficial owner, or we may issue warrants under a written warrant agreement with a warrant agent specified in a prospectus
supplement. A warrant agent would act solely as our agent in connection with the warrants of a particular series and would not assume
any obligation or relationship of agency or trust for or with any holders or beneficial owners of those warrants.
The following are some of the warrant terms that
could be described in a prospectus supplement:
| ● | the title of the warrants; |
| ● | the aggregate number of warrants; |
| ● | the price or prices at which the warrants will be issued; |
| ● | the designation, number and terms of the shares of common stock that may be purchased upon exercise of the warrants; |
| ● | the date, if any, on and after which the warrants and the securities offered with the warrants, if any, will be separately transferable; |
| ● | the purchase price for each security purchasable on exercise of the warrants; |
| ● | the dates on which the right to purchase certain securities upon exercise of the warrants will begin and end; |
| ● | the minimum or maximum number of shares of common stock that may be purchased at any one time upon exercise of the warrants; |
| ● | any anti-dilution provisions or other adjustments to the exercise price of the warrants; |
| ● | the terms of any right that we may have to redeem the warrants; |
| ● | the effect of any merger, consolidation, sale or other transfer of our business on the warrants and the applicable warrant agreement,
if any; |
| ● | information with respect to book-entry procedures, if any; |
| ● | a discussion of material U.S. federal income tax considerations; and |
| ● | other material terms, including terms relating to transferability, exchange, exercise or amendments of the warrants. |
Unless otherwise provided in the applicable prospectus
supplement, the warrants and the warrant agreements will be governed by the laws of the State of New York.
Options
As of December 31, 2021, options to purchase
2,259,020 shares of our common stock at a weighted average exercise price equal to approximately $4.42 per share were outstanding.
Convertible Notes
On August 25, 2021, we completed exchanges,
or the Exchanges, of our outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders
of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65 million principal amount of
our outstanding 2021 Notes for an aggregate of $28.75 million principal amount of newly issued 7.50% Senior Secured Convertible Notes
due 2024, or the 2024 Notes, $25.90 million in cash, and approximately $1.1 million in cash representing accrued and unpaid interest
through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal
amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of our common stock), subject to adjustment
in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of our
common stock on the NYSE American on August 13, 2021.
Delaware Anti-Takeover Law Governance and Certain Charter Provisions
We have elected not to be subject to Section 203
of the Delaware General Corporation Law. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation
from engaging in a “business combination” with any “interested stockholder” for three years following the date
that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of our
board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the interested
stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A “business
combination” includes, among other things, a merger or consolidation involving us and the “interested stockholder” and
the sale of more than 10% of our assets. In general, an “interested stockholder” is any entity or person beneficially owning
15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.
Our board of directors may, at any time, authorize
the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right
to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares,
together with a premium, before the redemption of our common stock. The ability of our board of directors to issue shares of preferred
stock without any further action on the part of our stockholders may impede a takeover of our company.
NYSE American and Tel Aviv Stock Exchange
Our common stock is listed on both the NYSE American
and the TASE under the symbol “PLX.”
DESCRIPTION OF DEBT SECURITIES
We may issue debt securities, in one or more series,
as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with
any other unsubordinated debt that we may have and may be secured or unsecured. The subordinated debt securities will be subordinate and
junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all or some portion of
our senior indebtedness. Any convertible debt securities that we may issue will be convertible into or exchangeable for common stock,
preferred stock or other securities of ours or of a third party. Conversion may be mandatory or at your option and would be at prescribed
conversion rates.
The debt securities will be issued under one or
more indentures, which are contracts between us and a national banking association or other eligible party, as trustee. While the terms
we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular
terms of any debt securities that we may offer in more detail in a prospectus supplement (and any free writing prospectus).
We will issue the senior notes under the senior
indenture that we will enter into with the trustee named in the senior indenture. We will issue the subordinated notes under the subordinated
indenture that we will enter into with the trustee named in the subordinated indenture. We will file forms of these documents as exhibits
to an amendment to the registration statement of which this prospectus is a part. We use the term “indentures” to refer to
both the senior indenture and the subordinated indenture.
The indentures will be qualified under the Trust
Indenture Act of 1939, as amended, or the Trust Indenture Act. We use the term “indenture trustee” to refer to either the
senior trustee or the subordinated trustee, as applicable.
The following summaries of the material provisions
of the senior notes, the subordinated notes and the indentures are not complete and are qualified in their entirety by reference to all
of the provisions of the indenture applicable to a particular series of debt securities. You should read the applicable prospectus supplement
(and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered,
as well as the complete indentures that contain the terms of the debt securities. Forms of indentures will be filed as exhibits to an
amendment to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing
the terms of the debt securities being offered will be filed as exhibits to an amendment to the registration statement of which this prospectus
is a part or will be incorporated by reference from reports that we file with the Commission. Except as we may otherwise indicate, the
terms of the senior indenture and the subordinated indenture are identical.
The following are some of the terms relating to
a series of debt securities that could be described in a prospectus supplement:
| ● | principal amount being offered, and, if a series, the total amount authorized and the total amount outstanding; |
| ● | any limit on the amount that may be issued; |
| ● | whether we will issue the series of debt securities in global form and, if so, the terms and who the depositary will be; |
| ● | principal amount due at maturity, and whether the debt securities will be issued with any original issue discount; |
| ● | whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a
United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts; |
| ● | annual interest rate, which may be fixed or variable, or the method for determining the rate, the date interest will begin to accrue,
the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; |
| ● | whether the debt securities will be secured or unsecured, and the terms of any secured debt; |
| ● | terms of the subordination of any series of subordinated debt; |
| ● | place where payments will be payable; |
| ● | restrictions on transfer, sale or other assignment, if any; |
| ● | our right, if any, to defer payment of interest and the maximum length of any such deferral period; |
| ● | date, if any, after which, the conditions upon which, and the price at which we may, at our option, redeem the series of debt securities
pursuant to any optional or provisional redemption provisions, and any other applicable terms of those redemption provisions; |
| ● | provisions for a sinking fund, purchase or other analogous fund, if any; |
| ● | date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions
or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities; |
| ● | whether the indenture will restrict our ability or the ability of our subsidiaries to: |
| o | incur additional indebtedness; |
| o | issue additional securities; |
| o | pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries; |
| o | place restrictions on our subsidiaries’ ability to pay dividends, make distributions or transfer assets; |
| o | make investments or other restricted payments; |
| o | sell or otherwise dispose of assets; |
| o | enter into sale-leaseback transactions; |
| o | engage in transactions with shareholders or affiliates; |
| o | issue or sell stock of our subsidiaries; or |
| o | effect a consolidation or merger; |
| ● | whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial
ratios; |
| ● | a discussion of any material or special U.S. federal income tax considerations applicable to the debt securities; |
| ● | information describing any book-entry features; |
| ● | procedures for any auction or remarketing, if any; |
| ● | whether the debt securities are to be offered at a price such that they will be deemed to be offered at an “original issue discount”
as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended; |
| ● | denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple
thereof; |
| ● | if other than dollars, the currency in which the series of debt securities will be denominated; and |
| ● | any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any events of
default that are in addition to those described in this prospectus or any covenants provided with respect to the debt securities that
are in addition to those described above, and any terms that may be required by us or advisable under applicable laws or regulations or
advisable in connection with the marketing of the debt securities. |
Conversion or Exchange Rights
We will set forth in the applicable prospectus
supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or exchangeable for common
stock, preferred stock or other securities of ours, including the conversion or exchange rate, as applicable, or how it will be calculated,
and the applicable conversion or exchange period. We will include provisions as to whether conversion or exchange is mandatory, at the
option of the holder or at our option. We may include provisions pursuant to which the number of our securities that the holders of the
series of debt securities receive upon conversion or exchange would, under the circumstances described in those provisions, be subject
to adjustment, or pursuant to which those holders would, under those circumstances, receive other property upon conversion or exchange,
for example in the event of our merger or consolidation with another entity.
Consolidation, Merger or Sale
The indentures in the forms to be filed as exhibits
to an amendment to the registration statement of which this prospectus is a part will not contain any covenant that restricts our ability
to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor
of ours or acquiror of such assets would have to assume all of our obligations under the indentures and the debt securities, as appropriate.
In addition, the terms of any securities that we may offer pursuant to this prospectus may limit our ability to merge or consolidate or
otherwise sell, convey, transfer or otherwise dispose of all or substantially all of our assets, which terms would be set forth in the
applicable prospectus supplement and supplemental indenture.
If the debt securities are convertible for our
other securities, the person with whom we consolidate or merge or to whom we sell all of our property would have to make provisions for
the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted
the debt securities before the consolidation, merger or sale.
Events of Default Under the Indenture
The following are events of default under the indentures
to be filed as exhibits to an amendment to the registration statement with respect to any series of debt securities that we may issue:
| ● | if we fail to pay interest when due and payable and our failure continues for 30 days and the time for payment has not been extended
or deferred; |
| ● | if we fail to pay the principal or premium, if any, when due and payable and the time for payment has not been extended or deferred; |
| ● | if we fail to observe or perform any other covenant contained in the debt securities or the indentures and our failure continues for
90 days after we receive notice from the indenture trustee or holders of at least 25% in aggregate principal amount of the outstanding
debt securities of the applicable series; and |
| ● | if specified events of bankruptcy, insolvency or reorganization occur. |
If an event of default with respect to debt securities
of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the indenture trustee
or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing,
and to the indenture trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest,
if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal
amount of and accrued interest, if any, of each issue of debt securities then outstanding would be due and payable without any notice
or other action on the part of the indenture trustee or any holder.
The holders of a majority in principal amount of
the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences,
except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or
event of default in accordance with the indenture. Any waiver shall cure the default or event of default.
Subject to the terms of the indentures, if an event
of default under an indenture occurs and continues, the indenture trustee would be under no obligation to exercise any of its rights or
powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such
holders have offered the indenture trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt
securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the indenture trustee, or exercising any trust or power conferred on the indenture trustee, with respect to the debt securities of
that series, provided that:
| ● | the direction so given by the holder is not in conflict with any law or the applicable indenture; and |
| ● | subject to its duties under the Trust Indenture Act, the indenture trustee need not take any action that might involve it in personal
liability or might be unduly prejudicial to the holders not involved in the proceeding. |
A holder of the debt securities of any series will
have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if:
| ● | the holder has given written notice to the indenture trustee of a continuing event of default with respect to that series; |
| ● | the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,
and such holders have offered reasonable indemnity to the indenture trustee to institute the proceeding as trustee; and |
| ● | the indenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal
amount of the outstanding debt securities of that series other conflicting directions within 60 days after the notice, request and offer. |
These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on the debt securities.
We will periodically file statements with the indenture
trustee regarding our compliance with specified covenants in the indentures.
Supplemental Indenture
We and the indenture trustee may from time to time
and at any time enter into an indenture or supplemental indenture without the consent of any holders for one or more of the following
purposes:
| ● | to evidence the succession of another corporation, and the assumption by the successor corporation of our covenants, agreements and
obligations under the indenture and debt securities; |
| ● | to add to our covenants such new covenants, restrictions, conditions or provisions for the protection of the holders, and to make
the occurrence, or the occurrence and continuance, of a default in any of such additional covenants, restrictions, conditions or provisions
an event of default; |
| ● | to add to or change any of the provisions of the indenture to provide that bearer securities may be registrable as to principal, to
change or eliminate any restrictions on the payment of principal of or any premium or interest on bearer securities, to permit bearer
securities to be issued in exchange for registered securities, to permit bearer securities to be issued in exchange for bearer securities
of other authorized denominations or to permit or facilitate the issuance of securities in uncertificated form, provided that such action
shall not adversely affect the interests of the holders of the securities or any related coupons, including provisions necessary or desirable
to provide for or facilitate the administration of the trusts hereunder; |
| ● | to modify, eliminate or add to any of the provisions of the indenture to such extent as necessary to effect the qualification of the
indenture under the Trust Indenture Act, and to add to the indenture such other provisions as may be expressly permitted by the trust
indenture act, excluding however, the provisions referred to in Section 316(a)(2) of the Trust Indenture Act; |
| ● | to modify, eliminate or add to any of the provisions of the indenture; |
| ● | to cure any ambiguity or to correct or supplement any provision contained in the indenture or in any supplemental indenture that may
be defective or inconsistent with other provisions; |
| ● | to convey, transfer, assign, mortgage or pledge any property to or with the trustee; |
| ● | to make provisions in regard to matters or questions arising under the indenture, so long such other provisions to do not materially
affect the interest of any other holder of debt securities; |
| ● | to secure any series of security; and |
| ● | to evidence and provide for the acceptance and appointment of a successor trustee and to add or change any provisions of the indenture
as necessary to provide for or facilitate the administration of the trust by more than one trustee. |
In addition, we and the trustee, with the consent
of the holders of not less than 66-2/3% in aggregate principal of the outstanding debt securities of each series that is affected, may
from time to time and at any time enter into an indenture or supplemental indenture for the purpose of adding any provisions to or changing
in any manner the rights of the holders of the securities of such series and any related coupons of the indenture, provided that no such
supplemental indenture shall:
| ● | extend the fixed maturity of any securities, or reduce the principal amount thereof or premium, if any, or reduce the rate or extend
the time of payment of interest, without the consent of the holder so affected; |
| ● | reduce the aforesaid percentage of securities, the consent of the holders of which is required for any such supplemental indenture,
without the consent of all holders of outstanding series of debt securities; or |
| ● | modify any of the above provisions. |
Discharge
Each indenture to be filed as an exhibit to an
amendment to the registration statement will provide that we can elect to be discharged from our obligations with respect to one or more
series of debt securities, except for specified obligations, including obligations to:
| ● | register the transfer or exchange of debt securities of the series; |
| ● | replace stolen, lost or mutilated debt securities of the series; |
| ● | maintain paying agencies; |
| ● | hold monies for payment in trust; |
| ● | recover excess money held by the indenture trustee; |
| ● | compensate and indemnify the indenture trustee; and |
| ● | appoint any successor trustee. |
In order to exercise our rights to be discharged,
we must deposit with the indenture trustee money or government obligations, or a combination thereof, sufficient to pay all the principal
of, any premium and interest on, the debt securities of the series on the dates payments are due.
Form, Exchange and Transfer
We will issue the debt securities of each series
only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement or free writing
prospectus, in denominations of $1,000 and any integral multiple thereof. The indentures will provide that we may issue debt securities
of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository
Trust Company or another depositary named by us and identified in a prospectus supplement or free writing prospectus with respect to that
series.
At the option of the holder, subject to the terms
of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement or free writing
prospectus, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series,
in any authorized denomination and of like tenor and aggregate principal amount.
Subject to the terms of the indentures and the
limitations applicable to global securities set forth in the applicable prospectus supplement or free writing prospectus, holders of the
debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer
endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office
of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for
transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes
or other governmental charges.
We will name in the applicable prospectus supplement
or free writing prospectus the security registrar, and any transfer agent in addition to the security registrar, that we initially designate
for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve
a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place
of payment for the debt securities of each series.
If we elect to redeem the debt securities of any
series, we will not be required to:
| ● | issue, register the transfer of or exchange any debt securities of any series being redeemed in part during a period beginning at
the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption
and ending at the close of business on the day of the mailing; or |
| ● | register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion
of any debt securities we are redeeming in part. |
Information Concerning the Indenture Trustee
The indenture trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the
applicable indenture. Upon an event of default under an indenture, the indenture trustee must use the same degree of care as a prudent
person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the indenture trustee is under no obligation
to exercise any of the powers given it by an indenture at the request of any holder of debt securities unless it is offered reasonable
security and indemnity against the costs, expenses and liabilities that it might incur.
Payment and Paying Agents
Unless we otherwise indicate in the applicable
prospectus supplement or free writing prospectus, we will make payment of the interest on any debt securities on any interest payment
date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on
the regular record date for the interest.
We will pay principal of and any premium and interest
on the debt securities of a particular series at the office of the paying agents designated by us, except that, unless we otherwise indicate
in the applicable prospectus supplement or free writing prospectus, we may make interest payments by check that we will mail to the holder
or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus supplement or free writing prospectus, we will designate
an office or agency of the indenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities
of each series. We will name in the applicable prospectus supplement or free writing prospectus any other paying agents that we initially
designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities
of a particular series.
All money we pay to a paying agent or the indenture
trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two
years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter
may look only to us for payment thereof.
Governing Law
The indentures and the debt securities will be
governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.
Subordination of Subordinated Debt Securities
The subordinated debt securities will be subordinate
and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement or free writing
prospectus. The indentures in the forms initially filed as exhibits to the registration statement of which this prospectus is a part do
not limit the amount of indebtedness which we may incur, including senior indebtedness or subordinated indebtedness, and do not limit
us from issuing any other debt, including secured debt or unsecured debt.
PLAN OF DISTRIBUTION
We may sell the securities from time to time pursuant
to underwritten public offerings, negotiated transactions, at the market offerings, block trades or a combination of these methods. We
may sell the securities to or through underwriters or dealers, through agents or directly to one or more purchasers.
We may distribute securities from time to time
in one or more transactions:
| ● | at a fixed price or prices, which may be changed; |
| ● | at market prices prevailing at the time of sale; |
| ● | at prices related to such prevailing market prices; or |
Unless stated otherwise in the applicable prospectus
supplement, the obligations of any underwriter to purchase securities will be subject to certain conditions, and the underwriter will
be obligated to purchase all of the applicable securities if any are purchased. If a dealer is used in a sale, we may sell the securities
to the dealer as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at
the time of resale.
We or our agents may solicit offers to purchase
securities from time to time. Unless stated otherwise in the applicable prospectus supplement, any agent will be acting on a best-efforts
basis for the period of its appointment.
In connection with the sale of securities, underwriters
or agents may receive compensation (in the form of discounts, concessions or commissions) from us or from purchasers of securities for
whom they may act as agents. Underwriters may sell securities to or through dealers, and such dealers may receive compensation in the
form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for whom they may act as agents.
Underwriters, dealers and agents that participate in the distribution of securities may be deemed to be underwriters, as that term is
defined in the Securities Act, and any discounts or commissions received by them from us and any profits on the resale of the securities
by them may be deemed to be underwriting discounts and commissions under the Securities Act. We will identify any such underwriter or
agent, and we will describe any compensation paid to them, in the related prospectus supplement.
Underwriters, dealers and agents may be entitled
under agreements with us to indemnification against and contribution toward certain civil liabilities, including liabilities under the
Securities Act.
If stated in the applicable prospectus supplement,
we will authorize agents and underwriters to solicit offers by certain specified institutions or other persons to purchase securities
at the public offering price set forth in the prospectus supplement under delayed delivery contracts providing for payment and delivery
on a specified date in the future. Institutions with whom these contracts may be made include commercial and savings banks, insurance
companies, pension funds, investment companies, educational and charitable institutions, and other institutions, but shall in all cases
be subject to our approval. These contracts will be subject only to those conditions set forth in the applicable prospectus supplement
and the applicable prospectus supplement will set forth the commission payable for solicitation of these contracts. The obligations of
any purchaser under any such contract will be subject to the condition that the purchase of the securities shall not be prohibited at
the time of delivery under the laws of the jurisdiction to which the purchaser is subject. The underwriters and other agents will not
have any responsibility in respect of the validity or performance of these contracts.
The securities may or may not be listed on a national
securities exchange or traded in the over-the-counter market, as set forth in the applicable prospectus supplement. No assurance can be
given as to the liquidity of the trading market for any of our securities. Any underwriter may make a market in these securities. However,
no underwriter will be obligated to do so, and any underwriter may discontinue any market-making at any time, without prior notice.
If underwriters or dealers are used in the sale,
until the distribution of the securities is completed, Commission rules may limit the ability of any underwriters and selling group
members to bid for and purchase the securities. As an exception to these rules, representatives of any underwriters are permitted to engage
in certain transactions that stabilize the price of the securities. These transactions may consist of bids or purchases for the purpose
of pegging, fixing or maintaining the price of the securities. If the underwriters create a short position in the applicable securities
in connection with any offering (in other words, if they sell more securities than are set forth on the cover page of the applicable
prospectus supplement) the representatives of the underwriters may reduce that short position by purchasing securities in the open market.
The representatives of the underwriters may also elect to reduce any short position by exercising all or part of any overallotment option
we may grant to the underwriters, as described in the prospectus supplement. The representatives of the underwriters may also impose a
penalty bid on certain underwriters and selling group members. This means that if the representatives purchase securities in the open
market to reduce the underwriters’ short position or to stabilize the price of the securities, they may reclaim the amount of the
selling concession from the underwriters and selling group members who sold those shares as part of the offering.
In general, purchases of a security for the purpose
of stabilization or to reduce a short position could cause the price of the security to be higher than it might be in the absence of those
purchases. The imposition of a penalty bid might also have an effect on the price of the securities to the extent that it discourages
resales of the securities. The transactions described above may have the effect of causing the price of the securities to be higher than
it would otherwise be. If commenced, the representatives of the underwriters may discontinue any of the transactions at any time. In addition,
the representatives of any underwriters may determine not to engage in those transactions or that those transactions, once commenced,
may be discontinued without notice.
Certain of the underwriters or agents and their
associates may engage in transactions with and perform services for us or our affiliates in the ordinary course of their respective businesses.
In no event will the commission or discount received
by any Financial Industry Regulatory Authority, or FINRA, member or independent broker-dealer participating in a distribution of securities
exceed 8% of the aggregate principal amount of the offering of securities in which that FINRA member or independent broker-dealer participates.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus is part of a registration statement
on Form S-3 that we filed with the Commission under the Securities Act. You should rely only on the information contained in this
prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different information.
You should not assume that the information in this prospectus is accurate as of any date other than the date on the front cover of this
prospectus, regardless of the time of delivery of this prospectus or any sale of securities.
We file annual, quarterly and current reports,
proxy statements and other information with the Commission. Our Commission filings, including the registration statement and exhibits,
are available to the public at the Commission’s website at http://www.sec.gov. You can request copies of these documents by writing
to the Commission and paying a fee for the copying cost. In addition, since we are also listed on the TASE, we submit copies of all our
filings with the Commission to the Israeli Securities Authority and the TASE. Such copies can be retrieved electronically through the
TASE’s internet messaging system (www.maya.tase.co.il) and through the MAGNA distribution site of the Israeli Securities Authority
(www.magna.isa.gov.il).
We maintain an Internet site at www.protalix.com.
Webcasts of presentations we make at certain conferences may also be available on our website from time to time. We have not incorporated
by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.
This prospectus does not contain all of the information
included in the registration statement. We have omitted certain parts of the registration statement in accordance with the rules and
regulations of the Commission. For further information, we refer you to the registration statement, including its exhibits and schedules,
that may be found at the Commission’s website at http://www.sec.gov. Statements contained in this prospectus and any accompanying
prospectus supplement about the provisions or contents of any contract, agreement or any other document referred to are not necessarily
complete. Please refer to the actual exhibit for a more complete description of the matters involved.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Commission allows us to “incorporate
by reference” the information we file with the Commission, which means we can disclose important information to you by referring
you to those documents. The information we incorporate by reference is an important part of this prospectus, and certain information that
we will later file with the Commission will automatically update and supersede this information. We incorporate by reference the documents
listed below as well as any future filings we make with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (excluding, unless otherwise provided therein or herein, documents not deemed “filed” with the Commission and information
furnished pursuant to Item 2.02 and Item 7.01 on any Current Report on Form 8-K or certain exhibits furnished pursuant to Item 9.01
of Form 8-K) after the date of the initial registration statement and prior to the effectiveness of this registration statement,
and any filings made after the date of this prospectus until we sell all of the securities under this prospectus. The following documents
filed with the Commission are incorporated by reference in this prospectus:
Copies of these filings are available at no cost
on our website, www.protalix.com. In addition, you may request a copy of these filings and any amendments thereto at no cost, by writing
or telephoning us. Those copies will not include exhibits to those documents unless the exhibits are specifically incorporated by reference
in the documents or unless you specifically request them. You may also request copies of any exhibits to the registration statement at
no cost. Please direct your request to:
Eyal Rubin
Sr. Vice President and Chief Financial Officer
Protalix BioTherapeutics, Inc.
2 University Plaza, Suite 100
Hackensack, NJ 07601
(201) 696-9345
You should rely only on the information in this
prospectus, any prospectus supplement, any applicable free writing prospectus and the documents that are incorporated by reference. We
have not authorized anyone else to provide you with different information. We are not offering these securities in any state where the
offering is prohibited by law. You should not assume that the information in this prospectus, any prospectus supplement, any applicable
free writing prospectus or any incorporated document is accurate as of any date other than the date of the document.
LEGAL MATTERS
The validity of the issuance of the shares of common
stock offered hereby will be passed upon for us by Mayer Brown LLP, New York, New York.
EXPERTS
The financial statements incorporated in this prospectus
by reference to the Annual Report on Form 10-K for the year ended December 31, 2021 have been so incorporated in reliance on the report
of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth an estimate of the
fees and expenses relating to the offering of the securities being registered hereby, other than underwriting discounts and commissions,
all of which shall be borne by the Registrant. All of such fees and expenses, except for the Commission registration fee, are estimated:
SEC registration fee | |
$ | 9,270** | |
Transfer agent fees and expenses | |
| * | |
Legal fees and expenses | |
| * | |
Printing fees and expenses | |
| * | |
Accounting fees and expenses | |
| * | |
Miscellaneous fees and expenses | |
| * | |
Total | |
| * | |
* These fees are calculated based on the securities offered and the
number of issuances and accordingly cannot be estimated at this time. The applicable prospectus supplement will set forth the estimated
amount of expenses of any offering of securities.
** Of this amount, $5,557.01
was previously paid.
Item 15. Indemnification of Directors and Officers.
General Corporation Law
We indemnify our directors and officers to the
maximum extent permitted by Delaware law for the costs and liabilities of acting or failing to act in an official capacity. In addition,
we have entered into indemnification agreements with each of our executive officers and directors to provide them with the maximum indemnification
allowed under our amended and restated bylaws and applicable Delaware law, including indemnification for all judgments and expenses incurred
as the result of any lawsuit in which such person is named as a defendant by reason of being our director, officer or employee, to the
extent indemnification is permitted by the laws of Delaware. We believe that the indemnification agreements will enhance our ability to
continue to attract and retain qualified individuals to serve as directors and officers.
The articles of association of Protalix Ltd., our
wholly owned subsidiary incorporated in Israel, allow it to exculpate, indemnify, and insure its office holders to the fullest extent
permitted by Israeli law, as described below. Accordingly, Protalix Ltd. has entered into indemnification agreements with each of its
officers and directors undertaking to indemnify them to the fullest extent permitted by Israeli law. As required by Israeli law, the indemnification
is limited to events determined as foreseeable by the board of directors of Protalix Ltd. based on the activities of Protalix Ltd. upon
adoption of the form of indemnification in 2016, and to an amount determined by the board of directors as reasonable under the circumstances.
We purchase and maintain a directors and officers
liability insurance policy that covers the liability of our directors and officers on a “claims made” basis for their ongoing
activity since December 28, 2006, with a limit of $20,000,000 for any one claim and in the aggregate for the period of insurance. The
policy also covers reasonable legal defense costs in Israel in accordance with Israeli law in addition to said limit.
Furthermore, we purchase and maintain a Side A Excess and Difference
In Conditions insurance that covers the non-indemnifiable liability of our directors and officers on a “claims made” basis
for their ongoing activity since December 28, 2006, with a limit of $15,000,000 for any one claim and in the aggregate for the period
of insurance. The policy also covers reasonable legal defense costs in Israel in accordance with Israeli law in addition to said limit.
As of the date of hereof, no claims for directors’
and officers’ liability insurance have been filed under those policies and neither we nor Protalix Ltd. is aware of any pending
or threatened litigation or proceeding involving any of our directors or officers, or those of Protalix Ltd., in which indemnification
is sought.
We have undertaken to fulfill and honor in all
respects the obligations of Protalix Ltd. pursuant to any indemnification agreements between Protalix Ltd. and its directors in effect
prior to December 31, 2006 and to provide any substitute director and the officers of Protalix Ltd. with similar indemnification
agreements. We further agreed that any provision of Protalix Ltd.’s charter documents that relate to exculpation and indemnification
of officers and directors of Protalix Ltd. will not be amended, repealed or otherwise modified in any manner that would adversely affect
the rights of the directors and officers, unless such modification is required by any applicable law.
Under Israeli law, an Israeli company may not exculpate
an office holder from liability for a breach of the duty of loyalty of the office holder. An Israeli company may exculpate an office holder
in advance from liability, in whole or in part, for damages caused due to a breach of duty of care owed to the company (other than in
the event that such liability arises out of a breach of duty of care to the company upon distribution) but only if a provision authorizing
such exculpation is inserted in its articles of association. Protalix Ltd.’s articles of association include such a provision.
An Israeli company may indemnify an office holder
in respect of certain liabilities or expenses either in advance of an event or following an event provided a provision authorizing such
indemnification is inserted in its articles of association. Protalix Ltd.’s articles of association contain such an authorization.
An Israeli company may indemnify an office holder against the following liabilities or expenses incurred for acts performed as an office
holder:
| (A) | financial liability imposed on or incurred by him or her in favor of another person pursuant to a judgment, settlement or arbitrator’s
award approved by a court; |
| (B) | reasonable litigation expenses, including attorneys’ fees, incurred by the office holder as a result of an investigation or
proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no
indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability,
such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation
or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
intent or with regard to a monetary sanction; |
| (C) | reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings
instituted against him or her by the company, on its behalf or by a third party or in connection with criminal proceedings in which the
office holder was acquitted or as a result of a conviction for a crime that does not require proof of criminal intent; and |
| (D) | a payment that the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the
Israeli Securities Law, 5278-1968, as amended, or the Israeli Securities Law, and reasonable litigation expenses, including attorneys’
fees, that the office holder incurred in connection with a proceeding under Chapters H’3, H’4 or I’1 of the Israeli
Securities Law. |
An undertaking provided in advance by an Israeli
company to indemnify an office holder with respect to (A), as abovementioned, must be limited to events that, in the opinion of the board
of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or
according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the
abovementioned events and amount or criteria. We are permitted to provide an office holder advance payments to cover expenses covered
under (D) above.
An Israeli company may insure an office holder
against the following liabilities incurred for acts performed as an office holder:
| ● | a breach of duty of care to the company or to a third party; |
| ● | a breach of duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to
believe that the act would not be detrimental to the interests of the company; |
| ● | a financial liability imposed on the office holder in favor of a third party in respect of an act performed in his or her capacity
as an office holder; and |
| ● | a payment that the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the
Israeli Securities Law and reasonable litigation expenses, including attorneys’ fees, that the office holder incurred in connection
with a proceeding under Chapters H’3, H’4 or I’1 of the Israeli Securities Law. |
An Israeli company may not insure, indemnify or
exculpate an office holder against any of the following:
| ● | a breach of duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not be detrimental to the interests of the company; |
| ● | a grossly negligent or intentional violation of an office holder’s duty of care; |
| ● | an act or omission committed with intent to derive illegal personal benefit; or |
| ● | a fine, civil fine, monetary sanction or ransom levied against the office holder. |
Under the Israeli law, exculpation, indemnification
and insurance of office holders of Protalix Ltd. must be approved by the board of directors of Protalix Ltd. and, in respect of directors
of Protalix Ltd., also by the stockholders of Protalix Ltd. Such approvals were properly obtained.
Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors and officers or persons controlling us pursuant to the foregoing provisions,
or otherwise, we have been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed
in the Securities Act, and is, therefore, unenforceable. With respect to insurance and indemnification for liabilities and expenses arising
under the Israeli Securities Law, such insurance and indemnification is permissible only to the extent described in this Item 6.
Item 16. List of Exhibits.
* To be filed by amendment or as an exhibit to a current report of
the Company on Form 8-K and incorporated herein by reference.
Item 17. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales
are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts
or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20 percent change in the maximum aggregate offering price set forth in “Calculation of Registration Fee” table
in the effective registration statement; and
(iii) To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement;
Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and
(a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs
is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of
the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus
filed pursuant to Rule 424(b) that is part of the registration statement.
(2) That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
(3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser:
(i) If the Registrant is relying on Rule 430B:
(A) Each prospectus filed by the Registrant
pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and
(B) Each prospectus required to be filed pursuant
to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of
the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such
form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described
in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement
to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
a part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was a part of the registration statement or made in
any such document immediately prior to such effective date; or
(ii) If the Registrant is subject to Rule 430C,
each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and
included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made
in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document immediately prior to such date of first use.
(5) That, for the purpose of determining
liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:
The undersigned Registrant undertakes that in a primary offering of
securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications,
the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus
of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating
to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;
(iii) The portion of any other free writing
prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or
on behalf of the undersigned Registrant; and
(iv) Any other communication that is an offer
in the offering made by the undersigned Registrant to the purchaser.
(b) The undersigned Registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report
pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed
in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the respective Registrant of expenses incurred or paid by a director, officer, or controlling person of the
Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
SIGNATURES
POWER OF ATTORNEY
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of Tel Aviv, State of Israel, on the 20th day of April, 2022.
|
PROTALIX BIO THERAPEUTICS, INC. |
|
|
|
|
|
By: |
/s/ Dror Bashan |
|
|
Dror Bashan |
|
|
President and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints, jointly and severally, Dror Bashan and Eyal Rubin, and each one of
them, his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him and in his name, place and stead,
in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to
sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant
to Rule 462(b) promulgated under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file
the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, and each of them full power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying
and confirming that each of said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully
do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:
Signatures |
|
Capacity |
|
Date |
|
|
|
|
|
/s/ Dror Bashan |
|
President, Chief Executive |
|
April 20, 2022 |
Dror Bashan |
|
Officer (Principal Executive Officer) and Director |
|
|
|
|
|
|
|
/s/ Eyal Rubin |
|
Sr. Vice President, Chief Financial Officer, Treasurer and |
|
April 20, 2022 |
Eyal Rubin |
|
Secretary (Principal Financial and Accounting Officer) |
|
|
|
|
|
|
|
/s/ Zeev Bronfeld |
|
Chairman of the Board of Directors |
|
April 20, 2022 |
Zeev Bronfeld |
|
|
|
|
|
|
|
|
|
/s/ Amos Bar Shalev |
|
Director |
|
April 20, 2022 |
Amos Bar Shalev |
|
|
|
|
|
|
|
|
|
/s/ Pol F. Boudes |
|
Director |
|
April 20, 2022 |
Pol F. Boudes |
|
|
|
|
|
|
|
|
|
/s/ David Granot |
|
Director |
|
April 20, 2022 |
David Granot |
|
|
|
|
|
|
|
|
|
/s/ Gwen A. Melincoff |
|
Director |
|
April 20, 2022 |
Gwen A. Melincoff |
|
|
|
|
|
|
|
|
|
/s/ Aharon Schwartz |
|
Director |
|
April 20, 2022 |
Aharon Schwartz, Ph.D. |
|
|
|
|
EXHIBIT INDEX
* To be filed by amendment or as an exhibit to a current report of
the Company on Form 8-K and incorporated herein by reference.
Protalix BioTherapeutics (AMEX:PLX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Protalix BioTherapeutics (AMEX:PLX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024